Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Author(s): Sarmad Said, Azikiwe C. Nwosu, Debabrata Mukherjee, German T. Hernandez

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
Formerly Current Drug Targets - Cardiovascular & Hematological Disorders

Volume 14 , Issue 1 , 2014

Become EABM
Become Reviewer
Call for Editor


Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are effective and safe oral incretin-based antihyperglycemic drugs. In preclinical studies, DPP-4 inhibitors have demonstrated cardiovascular benefits, independent of glycemic control, in patients with type-2 diabetes mellitus. Since 2005, various DPP-4 inhibitors (sitagliptin, linagliptin and saxagliptin) have been clinically available in the United States. Since 2013, alogliptin is the 4th approved DPP-4 inhibitor available on the market. Studies have shown that alogliptinis non-inferior to comparator drugs among newly diagnosed type 2 diabetes mellitus patients. Alogliptin can effectively be used as a single agent or as an add-on drug in combination with other glucose lowering drugs with favorable outcomes on glycemic control and HbA1C levels.

Keywords: Alogliptin, antihyperglycemic agents, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1, glucosedependent insulinotropic peptide, incretins, type 2 diabetes mellitus.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [64 - 70]
Pages: 7
DOI: 10.2174/1871529X14666140701095849

Article Metrics

PDF: 72